scorecardresearch
Friday, November 1, 2024
TopicCovaxin

Topic: Covaxin

After filing for Covaxin patent solo, Bharat Biotech to add ICMR as co-inventor

Hyderabad-based vaccine maker says not including ICMR in original patent application for Covaxin was ‘inadvertent error’ & ‘confidential agreement between them was not accessible’.

ICMR seeks retraction of BHU study linking high rate of adverse health events with Covaxin

Study, which said nearly 30 percent of Covaxin recipients suffered from one or other side-effects, is 'misleading', says ICMR head. Journal & authors threatened with legal action.

‘Fake news’ — Bharat Biotech, govt deny report on ‘discrepancies’ in Covaxin trial data

Medical news site STAT had cited internal documents to allege that Bharat Biotech had taken ‘questionable’ steps under political pressure to speed up development of Covaxin.

Covaxin safe for kids, generates higher antibody response in them than adults, says Lancet paper

The results of the phase ⅔ clinical trials of the indigenous Covid vaccine have been peer-reviewed and published in the The Lancet Infectious Diseases journal.

Drug authority clears Covaxin, Corbevax for children aged 5 to 12

DGCI also allowed emergency use of Zycov-D (Zydus Cadila vaccine) for children above 12 years.

As booster uptake lags in pvt sector, officials say health system can’t be in Covid mode forever

Third Covid vaccine dose available only in pvt hospitals. Health officials say routine procedures need to be brought back on track, but govt hospitals could be brought in if needed.

WHO move to suspend Covaxin’s UN supply won’t affect trips to UK, US & over 90 nations, govt says

Bharat Biotech is believed to have assured Government of India that it will ‘quickly’ reply to WHO about ‘deficiencies found in its manufacturing’ during an inspection last month.

Covaxin to be evaluated as Covid-19 vaccine candidate in US as FDA lifts clinical hold

As many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using Covaxin.

Covaxin supplies, trial group size — why there’s a delay in Covid vaccine for younger kids

Monthly Covaxin output between 5.5-6.5 cr. Country needs at least 15 cr doses for full coverage 15-18 age group. Choice of 6 μg dose reduced manufacturing capacity, says Bharat Biotech.

ICMR received Rs 171.74 cr in royalty from sale of Covaxin till 31 Jan, govt tells Rajya Sabha

ICMR and Bharat Biotech developed Covaxin together, and MoS Health Bharati Pawar says in written reply that the research body spent Rs 35 crore on its development.

On Camera

Geopolitics has reached third inflexion point since WW II, Cold War. An opportunity for India

While the present moment belongs to China, the next two decades can belong to India, provided we are ready to pursue bi-partisanship and take bold decisions.

Watch CutTheClutter: Flattening INR-USD rate, and debate on pros and cons of a ‘strong’ rupee

In Episode 1544 of CutTheClutter, Editor-in-Chief Shekhar Gupta looks at some top economists pointing to the pitfalls of ‘currency nationalism’ with data from 1991 to 2004.

All about Major Bob Khathing, whose daring expedition & diplomatic parleys secured Tawang for India

The decorated Naga officer from Manipur also served as envoy to Myanmar & Nagaland chief secy. Defence Minister Rajnath Singh inaugurated a museum dedicated to the Tawang hero Thursday.

From 2004 to 2024, bad news has come wrapped as good news for Congress

Congress is silently acknowledging it over-read verdict of last general election. You can see it in easy concession to SP. It will likely be more reasonable in Maharashtra & Jharkhand.